Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD65 | ISIN: US85209E1091 | Ticker-Symbol:
NASDAQ
13.11.24
21:41 Uhr
0,516 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SPRUCE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
SPRUCE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur SPRUCE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SPRUCE BIOSCIENCES Aktie jetzt für 0€ handeln
MoSpruce Biosciences GAAP EPS of -$0.21 beats by $0.041
MoSpruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates110SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine...
► Artikel lesen
28.10.Spruce Biosciences faces Nasdaq delisting notice1
28.10.SPRUCE BIOSCIENCES, INC. - 8-K, Current Report1
13.08.Spruce Biosciences GAAP EPS of -$0.22 beats by $0.01, revenue of $1.61M beats by $0.69M1
12.08.SPRUCE BIOSCIENCES, INC. - 10-Q, Quarterly Report1
12.08.SPRUCE BIOSCIENCES, INC. - 8-K, Current Report1
12.08.Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates70SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine...
► Artikel lesen
12.08.SPRB stock touches 52-week low at $0.42 amid market challenges1
18.06.SPRUCE BIOSCIENCES, INC. - 8-K, Current Report6
04.06.Spruce Biosciences, Inc.: Spruce Biosciences und HMNC Brain Health kündigen strategische Zusammenarbeit zur Entwicklung einer Behandlung für Major Depressive Disorder (MDD) an337Kombiniert Spruce's Produktkandidat Tildacerfont mit HMNC's Begleitdiagnostikum, dem proprietären Cortibon Genetic Selection Tool, zur Behandlung von MDD-Patienten, die auf CRF 1-Rezeptorantagonismus...
► Artikel lesen
04.06.Spruce Biosciences, Inc.: Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)293Pairs Spruce's Investigational Product Candidate, Tildacerfont, with HMNC's Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF1 Receptor...
► Artikel lesen
04.06.Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder1
03.06.SPRUCE BIOSCIENCES, INC. - 8-K, Current Report2
24.05.SPRUCE BIOSCIENCES, INC. - 8-K, Current Report2
13.05.Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates107SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare...
► Artikel lesen
14.03.Pre-market Movers: Spruce Biosciences, CCSC Technology, Turtle Beach, Lithium Americas, DHC Acquisition500OVERLAND PARK (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green CCSC Technology International Holdings Limited...
► Artikel lesen
13.03.Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates72SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1